[EN] N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS [FR] DÉRIVÉS N-PHÉNYL-2-(3-PHÉNYL-6-OXO-1,6-DIHYDROPYRIDAZINE-1-YL)ACÉTAMIDE POUR TRAITER LA MUCOVISCIDOSE
[EN] N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS [FR] DÉRIVÉS N-PHÉNYL-2-(3-PHÉNYL-6-OXO-1,6-DIHYDROPYRIDAZINE-1-YL)ACÉTAMIDE POUR TRAITER LA MUCOVISCIDOSE
[EN] N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS<br/>[FR] DÉRIVÉS N-PHÉNYL-2-(3-PHÉNYL-6-OXO-1,6-DIHYDROPYRIDAZINE-1-YL)ACÉTAMIDE POUR TRAITER LA MUCOVISCIDOSE
申请人:PROTEOSTASIS THERAPEUTICS INC
公开号:WO2018081377A1
公开(公告)日:2018-05-03
The present disclosure is directed to compounds that modulate, e.g., address underlying defects in cellular processing of CFTR (cystic fibrosis transmembrane conductance regulator) activity.